Switching product types
| . | After switching factor VIII product types . | |
|---|---|---|
| RR (95% CI) . | P . | |
| Clinically relevant inhibitor | ||
| Crude | 1.1 (0.6-1.8) | .83 |
| Adjusted | 0.9 (0.6-1.6) | .82 |
| High-titer inhibitor* | ||
| Crude | 1.0 (0.5-1.7) | .92 |
| Adjusted | 0.9 (0.5-1.6) | .68 |
| . | After switching factor VIII product types . | |
|---|---|---|
| RR (95% CI) . | P . | |
| Clinically relevant inhibitor | ||
| Crude | 1.1 (0.6-1.8) | .83 |
| Adjusted | 0.9 (0.6-1.6) | .82 |
| High-titer inhibitor* | ||
| Crude | 1.0 (0.5-1.7) | .92 |
| Adjusted | 0.9 (0.5-1.6) | .68 |
Values are relative risk (RR) (95% confidence interval). Data adjusted for baseline factor VIII activity level, ethnicity, factor VIII mutation type, age at first exposure, duration between ED, mean dose of factor VIII, and prophylaxis.
High-titer inhibitor was defined as a clinically relevant inhibitor with inhibitor titers of at least 5 Bethesda Units/mL at any time.